Enterprise Value
1.748M
Cash
5.595M
Avg Qtr Burn
-3.488M
Short % of Float
0.00%
Insider Ownership
0.00%
Institutional Own.
18.01%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Dipraglurant (mGlu5 NAM) Details Dystonia (Blepharospasm) | Phase 2 Update | |
ADX71149 Details Epilepsy | Phase 2 Update | |
Dipraglurant (mGlu5 NAM) Details Levodopa-induced dyskinesia associated with Parkinson’s disease | Failed Discontinued |